Humacyte director buys 30,000 shares at $0.594

Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased Humacyte common stock in the open market.

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased Humacyte common stock in the open market. On 2026-08-17, he bought 30,000 shares at a weighted average price of about $0.594 per share, resulting in direct holdings of 30,000 shares.

Insider Trade Summary

Net Buyer: 30,000 shares

Net Buy 1 txn

Insider Jones Keith Anthony

Role Director

Bought 30,000 shs ($18K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	30,000	$0.594	$18K

Holdings After Transaction: Common Stock — 30,000 shares (Direct)

Footnotes (1)

1. F1. The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.590 to $0.596. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 30,000 shares Weighted average purchase price: $0.594 per share Price range: $0.590–$0.596 per share +1 more

4 metrics

Shares purchased 30,000 shares Common Stock bought by director on 2026-08-17

Weighted average purchase price $0.594 per share Open-market purchase price for 30,000 shares

Price range $0.590–$0.596 per share Range of prices across multiple purchase executions

Shares owned after transaction 30,000 shares Direct ownership position following the reported purchase

Key Terms

weighted average price, open market, Reporting Person

3 terms

weighted average price financial

"The price is a weighted average price. The shares were purchased"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"Purchase in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Reporting Person regulatory

"The Reporting Person undertakes to provide upon request"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HUMA director Keith Anthony Jones report?

Director Keith Anthony Jones reported a purchase of 30,000 Humacyte (HUMA) shares on 2026-08-17. The shares were acquired in open-market transactions at a weighted average price of about $0.594 per share.

At what prices did Keith Anthony Jones buy Humacyte (HUMA) shares?

He bought Humacyte (HUMA) shares at per-share prices ranging from $0.590 to $0.596. The reported transaction price of about $0.594 is a weighted average across these multiple purchases.

How many Humacyte (HUMA) shares does Keith Anthony Jones hold after this transaction?

Following the reported transaction, Keith Anthony Jones directly holds 30,000 shares of Humacyte (HUMA) common stock. These holdings reflect the 30,000 shares purchased in the open-market transaction reported on 2026-08-17.

Was the Humacyte (HUMA) insider purchase made under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox was not affirmed, so the purchase was not identified as being under a 10b5-1 trading plan. The transaction is reported as an open-market purchase.

What is the total value of Keith Anthony Jones’s recent Humacyte (HUMA) share purchase?

Based on the weighted average price of about $0.594 per share and 30,000 shares purchased, the reported open-market transaction represents roughly $17,820 in Humacyte (HUMA) common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/19/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Keith Anthony

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		P		30,000	A	$0.594(1)	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.590 to $0.596. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Keith A. Jones by Dale A. Sander as Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)